• On 4 June 2026, Biogen reported that the FDA granted Breakthrough Therapy Designation to salanersen, its once-yearly antisense oligonucleotide for spinal muscular atrophy, based on Phase 1b data showing clinically meaningful motor-function gains and biomarker improvements in children with prior suboptimal gene therapy response.
• The designation, alongside an expansive three-trial Phase 3 program spanning presymptomatic infants to adults, positions salanersen as a potential new backbone therapy in SMA and underscores Biogen’s continued focus on high-need neurological indications.
• We’ll now examine how salanersen’s Breakthrough Therapy status and advancing Phase 3 program may reshape Biogen’s existing long-term growth narrative.

Find 47 companies with promising cash flow potential yet trading below their fair value.

Biogen Investment Narrative Recap

To own Biogen, you need to believe its newer neurology and rare disease pipeline can offset pressure on legacy MS drugs and pricing. In the near term, progress on Alzheimer’s asset LEQEMBI and other key launches still looks like the pivotal catalyst, while broad payer and biosimilar pressures remain the central risk. Salanersen’s Breakthrough Therapy Designation strengthens the long-term rare disease story but does not, on its own, change the most important short term swing factors.

Among recent updates, the FDA’s extended review of the subcutaneous LEQEMBI autoinjector stands out as especially relevant. Together with salanersen’s Phase 3 program, it highlights how Biogen is leaning into neurology convenience and breadth of indications as core drivers of its future, even as it contends with legal scrutiny around diranersen and uneven trial outcomes in Parkinson’s disease and Alzheimer’s.

Yet, while salanersen’s news is encouraging, investors should still be alert to how rising biosimilar and reimbursement pressure could...

Biogen's narrative projects $10.7 billion revenue and $2.2 billion earnings by 2029.

Uncover how Biogen's forecasts yield a $219.27 fair value, a 13% upside to its current price.

Exploring Other Perspectives

Some of the lowest ranked analysts were far more cautious, assuming revenues could fall to about US$8.6 billion and still see earnings reach roughly US$1.9 billion by 2029, so if you are weighing salanersen’s Breakthrough Therapy news against these views, it is worth recognizing how differently reasonable people can frame Biogen’s risks and opportunities.

Explore 6 other fair value estimates on Biogen - why the stock might be worth over 2x more than the current price!

Decide For Yourself

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Biogen research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Biogen research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Biogen's overall financial health at a glance.

Curious About Other Options?

Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:

• The future of work is here. Discover the 34 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
• Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 26 best rare earth metal stocks of the very few that mine this essential strategic resource.
• Invest in the nuclear renaissance through our list of 88 elite nuclear energy infrastructure plays powering the global AI revolution.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.